Sema4 Elements™

Data-driven reproductive & generational health solutions

Sema4 Elements™ offers a portfolio of information-driven genomic solutions, digital tools for patients and providers, and services that enable providers to treat patients holistically during their reproductive and generational health journey. This portfolio encompasses solutions for the diagnosis, treatment, and management of preventive, reproductive, and family care, and leverages robust science and state-of-the-art technologies to give providers and their patients more actionable information to improve health outcomes.

Solutions for wellness and the reproductive journey



*Prenatal molecular and biochemical testing is available for every disease on our ECS panel along with any additional testing required to support that pregnancy.

Carrier screening, from single gene to Sema4's largest panel of >500 genes, ethnicity-based panels, and enhanced testing for spinal muscular atrophy (SMA) which may detect silent carriers.

Noninvasive Prenatal testing, including Sema4 Noninvasive Prenatal Select which can detect chromosomal abnormalities as early as 9 weeks into pregnancy, and other noninvasive prenatal testing (NIPT).

Diagnostic sequencing and testing, including tests for Fragile X syndrome, congenital limb defects, microcephaly, Noonan syndrome, skeletal dysplasias, and recurrent pregnancy loss (including thrombophilia panel).

Biochemical testing, including testing for Tay-Sachs disease, Sandhoff disease, and Fabry disease.

Supplemental newborn screening - Natalis, a newborn test that screens for 193 treatable childhood conditions and analyzes a child's response to more than 40 commonly prescribed medications.

Hereditary Cancer testing, with screening for up to 113 genes, including our 38-gene High Prevalence Panel, for the assessment of inherited genetic risk for a broad range of cancer types, including breast and gynecological cancer.

sema4

Why Sema4 Elements?

Trusted partner for generational health solutions

- High-quality reproductive and hereditary cancer tests and services to support you and your patients from preconception to birth and beyond
- State-of-the-art technology to ensure high detection rates and accurate results
- Ongoing development of new test offerings, based on years of research and patient care

Commitment to service

- Dedicated Customer Success Team and personalized services to seamlessly align with your practice workflow
- Digital tools, such as the Sema4 provider portal, to make it easy for you to order and review test results, access detailed test information, and interface with your EMR
- Multilingual genetic counseling services for your patients and practice, including education, assistance in interpreting results, and guidance on care options

Support for patients and providers

- In-network with the majority of national and regional insurers
- Dedicated to helping providers and patients navigate the billing landscape, with pre-authorization services for providers and benefits investigation services for patients
- Patient-friendly billing policies, including competitive self-pay prices and financial assistance programs
- Patients can track their tests, view results, and access educational materials through the Sema4 patient portal and learn about the various stages of their pregnancy through our Pregnancy Journey digital resource tool

Learn more at **sema4.com/Elements.**

Sema4 Expanded Carrier Screen with Personalized Residual Risk

Screening for 502 genes, powered by advanced sequencing technologies.

Expansive — Our largest pan-ethnic carrier screen of 502 genes associated with severe or progressive inherited disorders. Detects more high-risk pregnancies than traditional carrier screening (CF and SMA) alone by identifying up to 30 times as many carrier couples.* **Prenatal diagnostic testing is available for all genes on our Expanded Carrier Screen.**

Flexible — Prefer to screen for a smaller panel of genes? Sema4 can accommodate any selection of 502 genes you would like to test, including single gene testing for partners.

Accurate — Sema4 Expanded Carrier Screen uses multiplatform testing technologies that are >99% clinically accurate, and provides proprietary personalized residual risk reporting based on molecular ancestry that is critical to better understand a patient's chance for passing on inherited disease.

Simple — Full-scale support with wrap-around genetic counseling and customer service, including explanation of results, patient video education, and multiple reporting options (EMR, portal, paper).

The American College of Obstetricians and Gynecologists (ACOG) recommends carrier screening be offered to all women who are pregnant or planning to become pregnant. "Carrier screening and counseling ideally should be performed before pregnancy because this enables couples to learn about their reproductive risk and consider the most complete range of reproductive options." (ACOG Committee Opinion No. 691, March 2017). For more information, visit **www.acog.org**.

Expanded Carrier Screening (502 genes) with Personalized Residual Risk (Validation Study). Sema4 (2021).

sema4